Latest Thesis
Zimmer Biomet: medtech durability still has to prove procedure demand, margin quality and cash conversion
ZBH has an annual revenue baseline of $8.2B, latest revenue marker of $2.1B Q1 2026, annual net income of $705.1M and cash of $424.2M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
Recent Reports
Compact report index for this company.
ReportTypeUpdatedReadActions
Zimmer Biomet: medtech durability still has to prove procedure demand, margin quality and cash conversionZBH has an annual revenue baseline of $8.2B, latest revenue marker of $2.1B Q1 2026, annual net income of $705.1M and cash of $424.2M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.NYSEMay 20, 2026Research reportReadSlides